Aartsma-RusA. (2017). FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther, 27:67–69.
2.
MercuriE, DarrasBT, ChiribogaCA, DayJW, CampbellC, ConnollyAM, IannacconeST, KirschnerJ, KuntzNL, et al. (2018). Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med, 378:625–635.
3.
FinkelRS, MercuriE, DarrasBT, ConnollyAM, KuntzNL, KirschnerJ, ChiribogaCA, SaitoK, ServaisL, et al. (2017). Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med, 377:1723–1732.
4.
AdamsD, Gonzalez-DuarteA, O'RiordanWD, YangC-C, UedaM, KristenAV, TournevI, SchmidtHH, CoelhoT, et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med, 379:11–21.
5.
BensonMD, Waddington-CruzM, BerkJL, PolydefkisM, DyckPJ, WangAK, Planté-BordeneuveV, BarrosoFA, MerliniG, et al. (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med, 379:22–31.
6.
MendellJR, GoemansN, LowesLP, AlfanoLN, BerryK, ShaoJ, KayeEM, MercuriE, Eteplirsen Study Group, et al. (2016). Longitudinal effect of Eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol, 79:257–271.
7.
Aartsma-RusA and KriegAM. (2017). FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen Saga. Nucleic Acid Ther, 27:1–3.
8.
PaikJ and DugganS. (2019). Volanesorsen: first global approval. Drugs, 79:1349–1354.
9.
SardhE, HarperP, BalwaniM, SteinP, ReesD, BissellDM, DesnickR, ParkerC, PhillipsJ, et al. (2019). Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med, 380:549–558.
10.
FitzgeraldK, WhiteS, BorodovskyA, BettencourtBR, StrahsA, ClausenV, WijngaardP, HortonJD, TaubelJ, et al. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med, 376:41–51.
11.
KhvorovaA. (2017). Oligonucleotide therapeutics—a new class of cholesterol-lowering drugs. N Engl J Med, 376:4–7.
12.
ZhaoZ, Tuakli-WosornuY, LagaceTA, KinchL, GrishinNV, HortonJD, CohenJC and HobbsHH. (2006). Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet, 79:514–523.
13.
HooperAJ, MaraisAD, TanyanyiwaDM and BurnettJR. (2007). The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, 193:445–448.
14.
Enrolment data from ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world. http://clinicaltrials.gov accessed November16, 2019.
15.
SabatineMS, GiuglianoRP, KeechAC, HonarpourN, WiviottSD, MurphySA, KuderJF, WangH, LiuT, et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 376:1713–1722.
16.
GiuglianoRP, PedersenTR, ParkJG, De FerrariGM, GaciongZA, CeskaR, TothK, Gouni-BertholdI, Lopez-MirandaJ, et al. (2017). Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 390:1962–1971.
17.
PrakashTP, GrahamMJ, YuJ, CartyR, LowA, ChappellA, SchmidtK, ZhaoC, AghajanM, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using tri-antennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res, 42:8796–8807.
18.
NairJK, WilloughbyJL, ChanA, CharisseK, AlamMR, WangQ, HoekstraM, KandasamyP, Kel'inAV, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc, 136:16958–16961.
19.
HuangX, LerouxJC and CastagnerB. (2017). Well-defined multivalent ligands for hepatocytes targeting via asialoglycoprotein receptor. Bioconjug Chem, 28:283–295.
20.
SharmaVK, OsbornMF, HasslerMR, EcheverriaD, LyS, UlashchikEA, Martynenko-MakaevYV, ShmanaiVV, ZatsepinTS, et al. (2018). Novel cluster and monomer-based GalNAc structures induce effective uptake of siRNAs in vitro and in vivo. Bioconjug Chem, 29:2478–2488.
